[go: up one dir, main page]

MX2022001655A - Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc). - Google Patents

Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).

Info

Publication number
MX2022001655A
MX2022001655A MX2022001655A MX2022001655A MX2022001655A MX 2022001655 A MX2022001655 A MX 2022001655A MX 2022001655 A MX2022001655 A MX 2022001655A MX 2022001655 A MX2022001655 A MX 2022001655A MX 2022001655 A MX2022001655 A MX 2022001655A
Authority
MX
Mexico
Prior art keywords
solid dispersions
sgc stimulator
relates
soxazol
fluorobenzyl
Prior art date
Application number
MX2022001655A
Other languages
English (en)
Inventor
Ahmad Hashash
Vasu Sethuraman
Craig Anthony Dunbar
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MX2022001655A publication Critical patent/MX2022001655A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con dispersiones sólidas de 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobencil)-5-(iso xazol-3-il)-1H-pirazol-3-il)pirimidin-4-il)amino)metil)propan-2-o l amorfo (compuesto I) o una sal farmacéuticamente aceptable de estos. También se refiere a composiciones farmacéuticas y formas farmacéuticas unitarias de dosificación oral que las comprenden, y uso de estas. (ver Fórmula) Compuesto 1.
MX2022001655A 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc). MX2022001655A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260910P 2015-11-30 2015-11-30
US201662359440P 2016-07-07 2016-07-07

Publications (1)

Publication Number Publication Date
MX2022001655A true MX2022001655A (es) 2022-03-11

Family

ID=57590822

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018006422A MX389961B (es) 2015-11-30 2016-11-22 Dispersiones sólidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
MX2022001656A MX2022001656A (es) 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
MX2022001655A MX2022001655A (es) 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2018006422A MX389961B (es) 2015-11-30 2016-11-22 Dispersiones sólidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
MX2022001656A MX2022001656A (es) 2015-11-30 2018-05-24 Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).

Country Status (12)

Country Link
US (4) US20190269619A1 (es)
EP (1) EP3383372B1 (es)
JP (3) JP6952707B2 (es)
KR (1) KR102841419B1 (es)
CN (4) CN116637077A (es)
AU (1) AU2016364976B2 (es)
BR (1) BR112018011154B1 (es)
CA (1) CA3006746C (es)
EA (1) EA201891315A1 (es)
IL (2) IL259493B (es)
MX (3) MX389961B (es)
WO (1) WO2017095697A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7098214B2 (ja) 2016-02-01 2022-07-11 サイクレリオン・セラピューティクス，インコーポレーテッド 非アルコール性脂肪性肝炎（ＮＡＳＨ）の処置のためのｓＧＣ刺激物質の使用
SG11201900125PA (en) * 2016-07-07 2019-02-27 Ironwood Pharmaceuticals Inc Novel processes for preparation of soluble guanylate cyclase stimulators
EA201990237A1 (ru) * 2016-07-07 2019-08-30 Сайклерион Терапьютикс, Инк. Новые способы получения стимуляторов растворимой гуанилатциклазы
US11389449B2 (en) 2017-09-14 2022-07-19 Cyclerion Therapeutics, Inc. Treatment of metabolic syndrome with an sGC stimulator
IL319883A (en) * 2018-01-10 2025-05-01 Cyclerion Therapeutics Inc Processes and intermediates for the preparation of cyclase-based geonalite fans
WO2019161534A1 (en) * 2018-02-22 2019-08-29 Ironwood Pharmaceuticals, Inc. Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
WO2019172420A1 (ja) * 2018-03-09 2019-09-12 協和発酵キリン株式会社 医薬組成物
JP7503781B2 (ja) * 2018-07-30 2024-06-21 株式会社リコー 粒子の製造方法、並びに、それにより製造された粒子及び医薬
WO2020027030A1 (en) * 2018-07-30 2020-02-06 Ricoh Company, Ltd. Method for producing particle, and particle produced by the method and medicament
EP4034113A4 (en) * 2019-09-23 2023-08-23 Bionomics Limited THERAPEUTIC FORMULATIONS AND THEIR USES
MX2022005158A (es) 2019-10-29 2022-06-08 Cyclerion Therapeutics Inc Tratamiento de nefropatia diabetica con un estimulador de guanilato ciclasa soluble (sgc).
CN116685308A (zh) * 2020-12-18 2023-09-01 Ucb生物制药有限责任公司 无定形固体分散体
US20240366596A1 (en) 2021-07-28 2024-11-07 Cyclerion Therapeutics, Inc. Treatment of hfpef in post-menopausal women with an sgc stimulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
AU2012225459A1 (en) * 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2014047111A1 (en) * 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR102502937B1 (ko) * 2013-03-15 2023-02-23 사이클리온 테라퓨틱스, 인크. ｓＧＣ 자극인자
EP3094327A1 (en) * 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

Also Published As

Publication number Publication date
US20190269619A1 (en) 2019-09-05
KR20180086497A (ko) 2018-07-31
EP3383372A1 (en) 2018-10-10
CA3006746A1 (en) 2017-06-08
IL290338B1 (en) 2023-01-01
EP3383372B1 (en) 2023-11-01
BR112018011154B1 (pt) 2023-09-26
JP2019501216A (ja) 2019-01-17
CN116942616A (zh) 2023-10-27
JP2022000464A (ja) 2022-01-04
US20250017862A1 (en) 2025-01-16
US20240293324A1 (en) 2024-09-05
IL259493A (en) 2018-07-31
EA201891315A1 (ru) 2018-12-28
BR112018011154A2 (pt) 2018-11-21
KR102841419B1 (ko) 2025-08-01
JP7641320B2 (ja) 2025-03-06
IL290338B2 (en) 2023-05-01
IL290338A (en) 2022-04-01
US20250255821A1 (en) 2025-08-14
CN116637077A (zh) 2023-08-25
IL259493B (en) 2022-03-01
WO2017095697A1 (en) 2017-06-08
CN116637076A (zh) 2023-08-25
JP7277534B2 (ja) 2023-05-19
AU2016364976A1 (en) 2018-06-14
MX2022001656A (es) 2022-03-11
CA3006746C (en) 2024-01-30
MX389961B (es) 2025-03-20
JP6952707B2 (ja) 2021-10-20
AU2016364976B2 (en) 2022-08-25
CN108883071A (zh) 2018-11-23
JP2023100851A (ja) 2023-07-19

Similar Documents

Publication Publication Date Title
MX2022001655A (es) Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
PH12020550745A1 (en) Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
PH12019501937A1 (en) Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
NZ763551A (en) Compounds useful for inhibiting cdk7
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
MY183536A (en) Pharmaceutical compositions comprising azd9291
PH12016501693A1 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
MY186908A (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
GEAP201814248A (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
WO2020123753A3 (en) Anellosomes for delivering intracellular therapeutic modalities
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
PH12017501397A1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
GR1008554B (el) Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα